Drugs / CP-461
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00036257 | Mar 2002 → Apr 2003 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00060710 | Jan 2003 → Dec 2004 | melanoma | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00042055 | Jul 2002 → Sep 2003 | Crohn disease | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00036075 | Aug 2001 → Dec 2005 | prostate cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00036036 | Jul 2001 → Jul 2003 | renal cell carcinoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00073489 | May 2001 → Dec 2003 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-461 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00036257 ↗ |
| Known as | OSI-461 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00073489 ↗ |
| Modality | Small molecule | — CHEMBL4068108 ↗ |
| Route | Oral | “CP-461 given twice-daily orally” NCT00036036 ↗ |